

Publications Marie-Anne Lorient

Dextromethorphan and memantine after ketamine analgesia: a randomized control trial. Martin E, Sorel M, Morel V, Marcaillou F, Picard P, Delage N, Tiberghien F, Crosmary MC, Najjar M, Colamarino R, Créach C, Lietar B, Brumauld de Montgazon G, Margot-Duclot A, **Lorient MA**, Narjoz C, Lambert C, Pereira B, Pickering G. Drug Des Devel Ther. 2019 Aug 2;13:2677-2688. doi: 10.2147/DDDT.S207350. eCollection 2019.

[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists]. **Lorient MA**, Masskouri F, Carni P, Le Malicot K, Seitz JF, Michel P, Legoux JL, Bouché O, André T, Faroux R, Delalogue S, Malka D, Guigay J, Thariat J, Thomas F, Barin-Le-Guellec C, Ciccolini J, Boyer JC, Étienne-Grimaldi MC. Bull Cancer. 2019 Sep;106(9):759-775. doi: 10.1016/j.bulcan.2019.04.013. Epub 2019 Jun 25. French.

Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability. Siguret V, Abdoul J, Delavenne X, Curis E, Carlo A, Blanchard A, Salem JE, Gaussem P, Funck-Brentano C, Azizi M, Mismetti P, **Lorient MA**, Lecompte T, Gouin-Thibault I. J Thromb Haemost. 2019 Oct;17(10):1670-1682. doi: 10.1111/jth.14541. Epub 2019 Jul 9.

P-glycoprotein influences urinary excretion of aldosterone in healthy individuals. Marques P, Courand PY, Gouin-Thibault I, Zhygalina V, Bergerot D, Salem JE, Funck-Brentano C, **Lorient MA**, Azizi M, Blanchard A. J Hypertens. 2019 Nov;37(11):2225-2231. doi: 10.1097/HJH.0000000000002150.

Dextromethorphan Analgesia in a Human Experimental Model of Hyperalgesia. Martin E, Narjoz C, Decleves X, Labat L, Lambert C, **Lorient MA**, Ducheix G, Dualé C, Pereira B, Pickering G. Anesthesiology. 2019 Aug;131(2):356-368. doi: 10.1097/ALN.0000000000002736.

Modeling the Outcome of Systematic TPMT Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis. Zarca K, Durand-Zaleski I, **Lorient MA**, Chatellier G, Pallet N. Mol Diagn Ther. 2019 Jun;23(3):429-438. doi: 10.1007/s40291-019-00398-x.

Development and validation of a UPLC-UV method for the quantification of thiopurine methyltransferase enzyme activity in human erythrocytes. Illamola SM, Echaabi AK, Mazon C, Deshayes S, **Lorient MA**, Pallet N. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Apr 15;1113:91-97. doi: 10.1016/j.jchromb.2019.03.014. Epub 2019 Mar 14.

Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. Danese E, Raimondi S, Montagnana M, Tagetti A, Langaee T, Borgiani P, Ciccacci C, Carcas AJ, Borobia AM, Tong HY, Dávila-Fajardo C, Rodrigues Botton M, Bourgeois S, Deloukas P, Caldwell MD, Burmester JK, Berg RL, Cavallari LH, Drozdka K, Huang M, Zhao LZ, Cen HJ, Gonzalez-Conejero R, Roldan V, Nakamura Y, Mushiroda T, Gong IY, Kim RB, Hirai K, Itoh K, Isaza C, Beltrán L, Jiménez-Varo E, Cañadas-Garre M, Giontella A, Kringen MK, Haug KBF, Gwak HS, Lee KE, Minuz P, Lee MTM, Lubitz SA, Scott S, Mazzaccara C, Sacchetti L, Genç E, Özer M, Pathare A, Krishnamoorthy R, Paldi A, Siguret V, **Lorient MA**, Kutala VK, Suarez-Kurtz G, Perini J, Denny JC, Ramirez AH, Mittal B, Rathore SS, Sagreiya H, Altman R, Shahin MHA, Khalifa SI, Limdi NA, Rivers C, Shendre A, Dillon C, Suriapranata IM, Zhou HH, Tan SL, Tatarunas V, Lesauskaite V, Zhang Y, Maitland-van der Zee AH, Verhoef TI, de Boer A, Taljaard M, Zambon CF, Pengo V, Zhang JE, Pirmohamed M, Johnson JA, Fava C. Clin Pharmacol Ther. 2019 Jun;105(6):1477-1491. doi: 10.1002/cpt.1323. Epub 2019 Feb 17.

Impact of Immunosuppressive Drugs on the Metabolism of T Cells. Pallet N, Fernández-Ramos AA, **Loriot MA**. *Int Rev Cell Mol Biol*. 2018;341:169-200. doi: 10.1016/bs.ircmb.2018.05.009. Epub 2018 Jun 19. Review.

Beta-1,4-galactosyltransferase 2 c.909C>T gene variant is predictive of on-clopidogrel platelet reactivity. Pallet N, Belleville-Rolland T, Savalle A, Lejeune M, Mauge L, Bertil S, **Loriot MA**, Gaussem P. *Pharmacogenomics*. 2018 Aug 1;19(12):937-945. doi: 10.2217/pgs-2018-0057. Epub 2018 Jul 18.

[Dihydropyrimidine déhydrogénase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks]. **Loriot MA**, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC. *Bull Cancer*. 2018 Apr;105(4):397-407. doi: 10.1016/j.bulcan.2018.02.001. Epub 2018 Feb 24. Review. French.

Smoking and Parkinson disease: Evidence for gene-by-smoking interactions. Lee PC, Ahmed I, **Loriot MA**, Mulot C, Paul KC, Bronstein JM, Ritz B, Elbaz A. *Neurology*. 2018 Feb 13;90(7):e583-e592. doi: 10.1212/WNL.0000000000004953. Epub 2018 Jan 19.

About molecular profile of lung cancer in Tunisian patients. Mezni F, Mlika M, Boussen H, Ghedira H, Fenniche S, Faten T, **Loriot MA**. *J Immunoassay Immunochem*. 2018;39(1):99-107. doi: 10.1080/15321819.2017.1407339.

Pooled analysis of the HLA-DRB1 by smoking interaction in Parkinson disease. Chuang YH, Lee PC, Vlaar T, Mulot C, **Loriot MA**, Hansen J, Lill CM, Ritz B, Elbaz A. *Ann Neurol*. 2017 Nov;82(5):655-664. doi: 10.1002/ana.25065. Epub 2017 Oct 26.

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing. Etienne-Grimaldi MC, Le Guellec CB, Boyer JC, Chatelut E, Evrard A, **Loriot MA**, Paci A, Royer B, Thomas F, Ciccolini J. *Semin Oncol*. 2017 Apr;44(2):159-160. doi: 10.1053/j.seminoncol.2017.06.001. Epub 2017 Jul 4.

A comprehensive characterization of the impact of mycophenolic acid on the metabolism of Jurkat T cells. Fernández-Ramos AA, Marchetti-Laurent C, Poindessous V, Antonio S, Petitgas C, Ceballos-Picot I, Laurent-Puig P, Bortoli S, **Loriot MA**, Pallet N. *Sci Rep*. 2017 Sep 5;7(1):10550. doi: 10.1038/s41598-017-10338-6.

6-mercaptopurine promotes energetic failure in proliferating T cells. Fernández-Ramos AA, Marchetti-Laurent C, Poindessous V, Antonio S, Laurent-Puig P, Bortoli S, **Loriot MA**, Pallet N. *Oncotarget*. 2017 Jun 27;8(26):43048-43060. doi: 10.18632/oncotarget.17889.

Pharmacogenetics of immunosuppressants: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics (RNPGx). Woillard JB, Chouchana L, Picard N, **Loriot MA**; French Network of Pharmacogenetics (RNPGX). *Thérapie*. 2017 Apr;72(2):285-299. doi: 10.1016/j.therap.2016.09.016. Epub 2017 Jan 30. Review.

Pharmacogénétique des immunosuppresseurs : état des connaissances et des pratiques – recommandations du Réseau national de pharmacogénétique (RNPGx). Woillard JB, Chouchana L, Picard N, **Loriot MA**; Réseau national de pharmacogénétique (RNPGx). *Thérapie*. 2017 Apr;72(2):269-284. doi: 10.1016/j.therap.2016.09.011. Epub 2017 Jan 3. French. No abstract available.

Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx). Picard N, Boyer JC, Etienne-Grimaldi MC, Barin-Le Guellec C, Thomas F, **Loriot MA**; French National Network of Pharmacogenetics (RNPGx). *Thérapie*. 2017 Apr;72(2):185-192. doi: 10.1016/j.therap.2016.09.014. Epub 2017 Jan 30. Review.

Traitements personnalisés grâce à la pharmacogénétique : niveaux de preuve et de recommandations du Réseau national de

pharmacogénétique (RNPGx). Picard N, Boyer JC, Etienne-Grimaldi MC, Barin-Le Guellec C, Thomas F, **Loriot MA**; Réseau national de pharmacogénétique (RNPGx). *Thérapie*. 2017 Apr;72(2):175-183. doi: 10.1016/j.therap.2016.09.007. Epub 2017 Jan 3. French.

Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial. Gallien S, Journot V, **Loriot MA**, Sauvageon H, Morlat P, Reynes J, Reliquet V, Chêne G, Molina JM; ANRS 099 ALIZE trial study group. *HIV Med*. 2017 Sep;18(8):537-545. doi: 10.1111/hiv.12488. Epub 2017 Feb 1.

Pegylated liposomal doxorubicin (Caelyx®) interference with the spectrophotometric Jaffe method for quantitative determination of creatinine in human plasma. Blel A, Orven Y, Pallet N, Chasse JF, Vedie B, **Loriot MA**, Paul JL, Narjoz C. *Clin Biochem*. 2017 May;50(7-8):455-457. doi: 10.1016/j.clinbiochem.2016.12.002. Epub 2016 Dec 14. No abstract available.

Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes. Flahault A, Anglicheau D, **Loriot MA**, Thervet E, Pallet N. *Pharmacogenomics*. 2017 Jan;18(2):165-173. doi: 10.2217/pgs-2016-0146. Epub 2016 Dec 15.

Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem JE, Narjoz C, Gaussem P, Beaune P, Funck-Brentano C, Azizi M, Mismetti P, **Loriot MA**. *J Thromb Haemost*. 2017 Feb;15(2):273-283. doi: 10.1111/jth.13577. Epub 2017 Feb 6.

Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. Isvoran A, Louet M, Vladioiu DL, Craciun D, **Loriot MA**, Villoutreix BO, Miteva MA. *Drug Discov Today*. 2017 Feb;22(2):366-376. doi: 10.1016/j.drudis.2016.09.015. Epub 2016 Sep 28. Review.

Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. Damon C, Luck M, Toullec L, Etienne I, Buchler M, Hurault de Ligny B, Choukroun G, Thierry A, Vigneau C, Moulin B, Heng AE, Subra JF, Legendre C, Monnot A, Yartseva A, Bateson M, Laurent-Puig P, Anglicheau D, Beaune P, **Loriot MA**, Thervet E, Pallet N. *Am J Transplant*. 2017 Apr;17(4):1008-1019. doi: 10.1111/ajt.14040. Epub 2016 Oct 7.

The effect of immunosuppressive molecules on T-cell metabolic reprogramming. Fernández-Ramos AA, Poindessous V, Marchetti-Laurent C, Pallet N, **Loriot MA**. *Biochimie*. 2016 Aug;127:23-36.

Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype. Pallet N, Etienne I, Buchler M, Hurault de Ligny B, Choukroun G, Colosio C, Thierry A, Vigneau C, Moulin B, Le Meur Y, Heng AE, Legendre C, Beaune P, **Loriot MA**, Thervet E. *Am J Transplant*. 2016 Mar 17.

A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients. Jannot AS, Vuillemin X, Etienne I, Buchler M, Hurault de Ligny B, Choukroun G, Colosio C, Thierry A, Vigneau C, Moulin B, Rerolle JP, Heng AE, Subra JF, Legendre C, Beaune P, **Loriot MA**, Thervet E, Pallet N. *Ther Drug Monit*. 2016 Apr;38(2):223-9.

High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study. Manfredi S, Bouché O, Rougier P, Dahan L, **Loriot MA**, Aparicio T, Etienne PL, Lafargue JP, Lécaillon C, Legoux JL, Le Malicot K, Maillard E, Lecomte T, Khemissa F, Breysacher G, Michel P, Mitry E, Bedenne L. *Mol Cancer Ther*. 2015 Dec;14(12):2782-8.

Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. Wang L, Aasly JO, Annesi G, Bardien S, Bozi M, Brice A, Carr J, Chung SJ, Clarke C, Crosiers D, Deuschländer A, Eckstein G, Farrer MJ, Goldwurm S, Garraux G, Hadjigeorgiou GM, Hicks AA, Hattori N, Klein C, Jeon B, Kim YJ, Lesage S, Lin JJ, Lynch T, Lichtner P, Lang AE, Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Opala G, Pihlstrøm L, Pramstaller PP, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Silburn PA, Theuns J, Tan EK, Tomiyama H, Toft M, Van Broeckhoven C, Uitti RJ, Wirdefeldt K, Wszolek Z, Xiomerisiou G, Yueh KC, Zhao Y, Gasser T, Maraganore DM, Krüger R, Sharma M; GEO-PD Consortium. *Neurology*. 2015 Oct 13;85(15):1283-92.

Gene expression profiling of cytochromes P450, ABC transporters and their principal transcription factors in the amygdala and prefrontal cortex of alcoholics, smokers and drug-free controls by qRT-PCR. Toselli F, de Waziers I, Dutheil M, Vincent M, Wilce PA, Dodd PR, Beaune P, **Loriot MA**, Gillam EM. *Xenobiotica*. 2015;45(12):1129-37.

Molecular insight into thiopurine resistance: transcriptomic signature in lymphoblastoid cell lines. Chouchana L, Fernández-Ramos AA, Dumont F, Marchetti C, Ceballos-Picot I, Beaune P, Gurwitz D, **Loriot MA**. *Genome Med*. 2015 Apr 18;7(1):37.

Expression in yeast, new substrates, and construction of a first 3D model of human orphan cytochrome P450 2U1: Interpretation of substrate hydroxylation regioselectivity from docking studies. Ducassou L, Jonasson G, Dhers L, Pietrancosta N, Ramassamy B, Xu-Li Y, **Loriot MA**, Beaune P, Bertho G, Lombard M, Mansuy D, André F, Boucher JL. *Biochim Biophys Acta*. 2015 Jul;1850(7):1426-37.

UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Etienne-Grimaldi MC, Boyer JC, Thomas F, Quaranta S, Picard N, **Loriot MA**, Narjoz C, Poncet D, Gagnieu MC, Ged C, Broly F, Le Morvan V, Bouquie R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C; Collective work by Groupe de Pharmacologie Clinique Oncologique (GPCO-Unicancer); French Réseau National de Pharmacogénétique Hospitalière (RNPGx). *Fundam Clin Pharmacol*. 2015 Jun;29(3):219-37.

A case of respiratory depression in a child with ultrarapid CYP2D6 metabolism after tramadol. Orliaguet G, Hamza J, Couloigner V, Denoyelle F, **Loriot MA**, Broly F, Garabedian EN. *Pediatrics*. 2015 Mar;135(3):e753-5.

Rituximab or azathioprine maintenance in ANCA-associated vasculitis. Chouchana L, Beaune P, **Loriot MA**. *N Engl J Med*. 2015 Jan 22;372(4):386.

Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. Pallet N, Jannot AS, El Bahri M, Etienne I, Buchler M, de Ligny BH, Choukroun G, Colosio C, Thierry A, Vigneau C, Moulin B, Le Meur Y, Heng AE, Subra JF, Legendre C, Beaune P, Alberti C, **Loriot MA**, Thervet E. *Am J Transplant*. 2015 Mar;15(3):800-5.

An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population. Krishna Kumar D, Shewade DG, **Loriot MA**, Beaune P, Sai Chandran BV, Balachander J, Adithan C. *Eur J Clin Pharmacol*. 2015 Feb;71(2):173-81.

Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers. Lenuzza N, Duval X, Nicolas G, Thévenot E, Job S, Videau O, Narjoz C, **Loriot MA**, Beaune P, Becquemont L, Mentré F, Funck-Brentano C, Alavoine L, Arnaud P, Delaforge M, Bénech H. *Eur J Drug Metab Pharmacokinet*. 2016 Apr;41(2):125-38.

Lack of replication of the GRIN2A-by-coffee interaction in Parkinson disease. Ahmed I, Lee PC, Lill CM, Searles Nielsen S, Artaud F, Gallagher LG, **Loriot MA**, Mulot C, Nacfer M, Liu T, Biernacka JM, Armasu S, Anderson K, Farin FM, Lassen CF, Hansen J, Olsen JH, Bertram L, Maraganore DM, Checkoway H, Ritz B, Elbaz A. *PLoS Genet*. 2014 Nov 20;10(11):e1004788. doi: 10.1371/journal.pgen.1004788. eCollection 2014 Nov.

Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. Narjoz C, Cessot A, Thomas-Schoemann A, Golmard JL, Huillard O, Boudou-Rouquette P, Behouche A, Taieb F, Durand JP, Dauphin A, Coriat R, Vidal M, Tod M, Alexandre J, **Loriot MA**, Goldwasser F, Blanchet B. *Invest New Drugs*. 2015 Feb;33(1):257-68.

Impact of aspirin and clopidogrel interruption on platelet function in patients undergoing major vascular surgery. Le Manach Y, Kahn D, Bachelot-Loza C, Le Sache F, Smadja DM, Remones V, **Loriot MA**, Coriat P, Gaussem P. *PLoS One*. 2014 Aug 20;9(8):e104491.

Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan. Boyer JC, Etienne-Grimaldi MC, Thomas F, Quaranta S, Picard N, **Loriot MA**, Poncet D, Gagnieu MC, Ged C, Broly F, Le Morvan V, Bouquié R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C. *Bull Cancer*. 2014;101(6):533-553.

Interindividual variability in TPMT enzyme activity: 10 years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring. Chouchana L, Narjoz C, Roche D, Golmard JL, Pineau B, Chatellier G, Beaune P, **Loriot MA**. *Pharmacogenomics*. 2014, 15(6):745-57

Association between high antitumor activity of oxaliplatin and cyclophosphamide and constitutional GSTM1 homozygous deletion in an advanced ovarian cancer patient. Gataa I, Emile G, **Loriot MA**, Goldwasser F, Alexandre J. *Chemotherapy*. 2013, 59(4):290-3.

Phenome-wide association studies on a quantitative trait: application to TPMT enzyme activity and thiopurine therapy in pharmacogenomics. Neuraz A, Chouchana L, Malamut G, Le Beller C, Roche D, Beaune P, Degoulet P, Burgun A, **Loriot MA**, Avillach P. *PLoS Comput Biol*. 2013, 9(12):e1003405.

A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone. Moreau C, Pautas E, Duverlie C, Berndt C, Andro M, Mahé I, Emmerich J, Lacut K, Le Gal G, Peyron I, Gouin-Thibault I, Golmard JL, **Loriot MA**, Siguret V. *Thromb Haemost*. 2014, 111(4):705-12.

Pooled Analysis of Iron-related Genes in Parkinson's Disease: Association with Transferrin. Rhodes SL, Buchanan DD, Ahmed I, Taylor KD, **Loriot MA**, Sinsheimer JS, Bronstein JM, Elbaz A, Mellick GD, Rotter JI, Ritz B. *Neurobiol Dis*. 2013 Oct 8. doi:p11: S0969-9961(13)00265-9. 10.1016/j.nbd.2013.09.019.

A case of 5-FU related severe toxicity associated to the p.Y186C DPYD variant. Zaanani A, Dumont LM, **Loriot MA**, Taieb J, Narjoz C. *Clin Pharmacol Ther*. 2013 Sep 13. doi: 10.1038/clpt.2013.183.

Effect of CYP2C9, VKORC1, CYP4F2 and GGX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. Krishna Kumar D, Shewade DG, **Loriot MA**, Beaune P, Balachander J, Sai Chandran BV, Adithan C. *Eur J Clin Pharmacol*. 2013 Sep 10.

The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Heckman MG, Elbaz A, Soto-Ortolaza AI, Serie DJ, Aasly JO, Annesi G, Auburger G, Bacon JA, Bocarska-Jedynak M, Bozi M, Brighina L, Chartier-Harlin MC, Dardiotis E, Destée A, Ferrarese C, Ferraris A, Fiske B, Gispert S, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyrtzi E, Lin CH, Lohmann K, **Loriot MA**, Lynch T, Mellick GD, Mutez E, Opala G, Park SS, Petrucci S, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Tomiyama H, Uitti RJ, Valente EM, Vassilatis DK, Vilariño-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Xiomerisiou G, Maraganore DM, Farrer MJ, Ross OA; Genetic Epidemiology Of Parkinson's Disease (GEO-PD) Consortium. *Neurobiol Aging*. 2014 Jan;35(1):266.e5-266.e14. doi: 10.1016/j.neurobiolaging.2013.07.013.

Poor response to thiopurine in inflammatory bowel disease: how to overcome therapeutic resistance? Chouchana L, Roche D, Jian R, Beaune P, **Loriot MA**. *Clin Chem*. 2013 Jul;59(7):1023-6. doi: 10.1373/clinchem.2012.195750.

Genetic resistance to warfarin therapy masked by amiodarone in a 2-year-old girl with mitral valve replacement. Moreau C, Bajolle F, Siguret V, **Loriot MA**, Bonnet D. *J Thromb Haemost*. 2013 Mar;11(3):555-72. doi: 10.1111/jth.12105.

Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients. Smires FZ, Habbal R, Moreau C, Assaidi A, **Loriot MA**, Nadifi S. *Pathol Biol (Paris)*. 2013 Jun;61(3):88-92. doi: 10.1016/j.patbio.2012.10.002.

Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Danese E, Montagnana M, Johnson JA, Rettie AE, Zamboni CF, Lubitz SA, Suarez-Kurtz G, Cavallari LH, Zhao L, Huang M, Nakamura Y, Mushiroda T, Kringen MK, Borgiani P, Ciccacci C, Au NT, Langae T, Siguret V, **Loriot MA**, Sagreya H, Altman

RB, Shahin MH, Scott SA, Khalifa SI, Chowbay B, Suriapranata IM, Teichert M, Stricker BH, Taljaard M, Botton MR, Zhang JE, Pirmohamed M, Zhang X, Carlquist JF, Horne BD, Lee MT, Pengo V, Guidi GC, Minuz P, Fava C. Clin Pharmacol Ther. 2012 Dec;92(6):746-56. doi: 10.1038/clpt.2012.184. Review.

[Vitamin K antagonists: from discovery to pharmacogenetics]. Moreau C, **Loriot MA**, Siguret V. Ann Biol Clin (Paris). 2012 Oct 1;70(5):539-51. doi: 10.1684/abc.2012.0740. Review. French.

Collapsing glomerulopathy associated lupus in a black female with homozygous APOL1 mutation. Kofman T, Narjoz C, Raimbourg Q, **Loriot MA**, Karras A, Roland M, Hill G, Jacquot C, Nochy D, Thervet E. Lupus. 2012 Nov;21(13):1459-62. doi: 10.1177/0961203312460114.

Early sorafenib-induced toxicity is associated with drug exposure and UGT1A9 genetic polymorphism in patients with solid tumors: a preliminary study. Boudou-Rouquette P, Narjoz C, Golmard JL, Thomas-Schoemann A, Mir O, Taieb F, Durand JP, Coriat R, Dauphin A, Vidal M, Tod M, **Loriot MA**, Goldwasser F, Blanchet B. PLoS One. 2012;7(8):e42875. doi: 10.1371/journal.pone.0042875.

Association between Parkinson's disease and the HLA-DRB1 locus. Ahmed I, Tamouza R, Delord M, Krishnamoorthy R, Tzourio C, Mulot C, Nacfer M, Lambert JC, Beaune P, Laurent-Puig P, **Loriot MA**, Charron D, Elbaz A. Mov Disord. 2012 Aug;27(9):1104-10. doi: 10.1002/mds.25035.

Large-scale replication and heterogeneity in Parkinson disease genetic loci. Sharma M, Ioannidis JP, Aasly JO, Annesi G, Brice A, Van Broeckhoven C, Bertram L, Bozi M, Crosiers D, Clarke C, Facheris M, Farrer M, Garraux G, Gispert S, Auburger G, Vilariño-Güell C, Hadjigeorgiou GM, Hicks AA, Hattori N, Jeon B, Lesage S, Lill CM, Lin JJ, Lynch T, Lichtner P, Lang AE, Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Opala G, Pramstaller PP, Pichler I, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Satake W, Silburn PA, Theuns J, Tan EK, Toda T, Tomiyama H, Uitti RJ, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Yueh KC, Zhao Y, Gasser T, Maraganore D, Krüger R; GEO-PD Consortium. Neurology. 2012 Aug 14;79(7):659-67. doi: 10.1212/WNL.0b013e318264e353.

Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma. Coudoré F, Roche D, Lefeuvre S, Faussot D, Billaud EM, **Loriot MA**, Beaune P. J Chromatogr Sci. 2012 Nov-Dec;50(10):877-84. doi: 10.1093/chromsci/bms085.

TPMT status determination: the simplest is the most effective? Chouchana L, Narjoz C, **Loriot MA**. J Crohns Colitis. 2012 Aug;6(7):807; author reply 808. doi: 10.1016/j.crohns.2012.04.003.

Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients. Smires FZ, Moreau C, Habbal R, Siguret V, Fadili S, Golmard JL, Assaidi A, Beaune P, **Loriot MA**, Nadifi S. J Clin Pharm Ther. 2012 Oct;37(5):594-8. doi: 10.1111/j.1365-2710.2012.01340.x.

Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Moreau C, Bajolle F, Siguret V, Lasne D, Golmard JL, Elie C, Beaune P, Cheurfi R, Bonnet D, **Loriot MA**. Blood. 2012 Jan 19;119(3):861-7. doi: 10.1182/blood-2011-07-365502.

Increased body mass index after kidney transplantation in activating transcription factor 6 single polymorphism gene carriers. Fougeray S, **Loriot MA**, Nicaud V, Legendre C, Thervet E, Pallet N. Transplant Proc. 2011 Nov;43(9):3418-22. doi: 10.1016/j.transproceed.2011.09.022.

Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Chouchana L, Narjoz C, Beaune P, **Loriot MA**, Roblin X. Aliment Pharmacol Ther. 2012 Jan;35(1):15-36. doi: 10.1111/j.1365-2036.2011.04905.x. Review.

Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Elbaz A, Ross OA, Ioannidis JP, Soto-Ortolaza AI, Moisan F, Aasly J, Annesi G, Bozi M, Brighina L, Chartier-Harlin MC, Destée A, Ferrarese C, Ferraris A,

Gibson JM, Gispert S, Hadjigeorgiou GM, Jasinska-Myga B, Klein C, Krüger R, Lambert JC, Lohmann K, van de Loo S, **Loriot MA**, Lynch T, Mellick GD, Mutez E, Nilsson C, Opala G, Puschmann A, Quattrone A, Sharma M, Silburn PA, Stefanis L, Uitti RJ, Valente EM, Vilariño-Güell C, Wirdefeldt K, Wszolek ZK, Xiromerisiou G, Maraganore DM, Farrer MJ; Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. *Ann Neurol*. 2011 May;69(5):778-92. doi: 10.1002/ana.22321.

High on-clopidogrel platelet reactivity: genotyping can help to optimize antiplatelet treatment. Szymezak J, Moreau C, **Loriot MA**, Durand E, Van Viet H, Desnos M, Gaussem P. *Thromb Res*. 2011 Jul;128(1):92-5. doi: 10.1016/j.thromres.2011.01.012.

[The DNA, the thread of destiny]. **Loriot MA**. *Rev Med Interne*. 2011 Jun;32(6):337-40. doi: 10.1016/j.revmed.2011.01.004. French.

Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes. Moreau C, Pautas E, Gouin-Thibault I, Golmard JL, Mahé I, Mulot C, **Loriot MA**, Siguret V. *J Thromb Haemost*. 2011 Apr;9(4):711-8. doi: 10.1111/j.1538-7836.2011.04213.x.

Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Saad M, Lesage S, Saint-Pierre A, Corvol JC, Zelenika D, Lambert JC, Vidailhet M, Mellick GD, Lohmann E, Durif F, Pollak P, Damier P, Tison F, Silburn PA, Tzourio C, Forlani S, **Loriot MA**, Giroud M, Helmer C, Portet F, Amouyel P, Lathrop M, Elbaz A, Durr A, Martinez M, Brice A; French Parkinson's Disease Genetics Study Group. *Hum Mol Genet*. 2011 Feb 1;20(3):615-27. doi: 10.1093/hmg/ddq497.

Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. Berge M, Guillemain R, Tréguet DA, Amrein C, Boussaud V, Chevalier P, Lillo-Lelouet A, Le Beller C, Laurent-Puig P, Beaune PH, Billaud EM, **Loriot MA**. *Eur J Clin Pharmacol*. 2011 Mar;67(3):253-60. doi: 10.1007/s00228-010-0914-2.

ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders. Dutheil F, Jacob A, Dauchy S, Beaune P, Scherrmann JM, Declèves X, **Loriot MA**. *Expert Opin Drug Metab Toxicol*. 2010 Oct;6(10):1161-74. doi: 10.1517/17425255.2010.510832. Review.

Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease. Dutheil F, Beaune P, Tzourio C, **Loriot MA**, Elbaz A. *Arch Neurol*. 2010 Jun;67(6):739-45. doi: 10.1001/archneurol.2010.101.

Optimization of initial tacrolimus dose using pharmacogenetic testing. Thervet E, **Loriot MA**, Barbier S, Buchler M, Fichoux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P, Moulin B, Le Meur Y, Heng AE, Subra JF, Beaune P, Legendre C. *Clin Pharmacol Ther*. 2010 Jun;87(6):721-6. doi: 10.1038/clpt.2010.17.

Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. Boige V, Mendiboure J, Pignon JP, **Loriot MA**, Castaing M, Barrois M, Malka D, Trégouët DA, Bouché O, Le Corre D, Miran I, Mulot C, Ducreux M, Beaune P, Laurent-Puig P. *J Clin Oncol*. 2010 May 20;28(15):2556-64. doi: 10.1200/JCO.2009.25.2106.

[The pharmacogenetics of vitamin K antagonists: still a matter for discussion]. Moreau C, Siguret V, **Loriot MA**. *Rev Med Interne*. 2010 May;31(5):361-8. doi: 10.1016/j.revmed.2009.07.014.

A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. Krüger R, Sharma M, Riess O, Gasser T, Van Broeckhoven C, Theuns J, Aasly J, Annesi G, Bentivoglio AR, Brice A, Djarmati A, Elbaz A, Farrer M, Ferrarese C, Gibson JM, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Klein C, Lambert JC, Lesage S, Lin JJ, Lynch T, Mellick GD, de Nigris F, Opala G, Prigione A, Quattrone A, Ross OA, Satake W, Silburn PA, Tan EK, Toda T, Tomiyama H, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Maraganore DM; Genetic Epidemiology of Parkinson's disease consortium. *Neurobiol Aging*. 2011 Mar;32(3):548.e9-18. doi: 10.1016/j.neurobiolaging.2009.11.021.

Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Pautas E, Moreau C, Gouin-Thibault I, Golmard JL, Mahé I, Legendre C, Taillandier-Hériché E, Durand-Gasselin B,

Houllier AM, Verrier P, Beaune P, **Loriot MA**, Siguret V. Clin Pharmacol Ther. 2010 Jan;87(1):57-64. doi: 10.1038/clpt.2009.178. E

[Chloroquine cardiotoxicity in long-term lupus therapy in two patients]. Saussine A, **Loriot MA**, Picard C, Lecerf V, Landry J, Scheer I, Voicu S, Leenhardt A, Ducrocq G, Maubec E, Crickx B. Ann Dermatol Venereol. 2009 Jun-Jul;136(6-7):530-5. doi: 10.1016/j.annder.2009.01.016.

Non-replication of association for six polymorphisms from meta-analysis of genome-wide association studies of Parkinson's disease: large-scale collaborative study. Evangelou E, Maraganore DM, Annesi G, Brighina L, Brice A, Elbaz A, Ferrarese C, Hadjigeorgiou GM, Krueger R, Lambert JC, Lesage S, Markopoulou K, Mellick GD, Meeus B, Pedersen NL, Quattrone A, Van Broeckhoven C, Sharma M, Silburn PA, Tan EK, Wirdefeldt K, Ioannidis JP; Genetic Epidemiology of Parkinson's Disease (GEOPD) Consortium. Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 5;153B(1):220-8. doi: 10.1002/ajmg.b.30980.

Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Dutheil F, Dauchy S, Diry M, Sazdovitch V, Cloarec O, Mellottée L, Bièche I, Ingelman-Sundberg M, Flinois JP, de Waziers I, Beaune P, Declèves X, Duyckaerts C, **Loriot MA**. Drug Metab Dispos. 2009 Jul;37(7):1528-38. doi: 10.1124/dmd.109.027011. Epub 2009 Apr 9.

Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.

Berge M, Guillemain R, Boussaud V, Pham MH, Chevalier P, Batisse A, Amrein C, Dannaoui E, **Loriot MA**, Lillo-Le Louet A, Billaud EM.

Transpl Infect Dis. 2009 Jun;11(3):211-9. doi: 10.1111/j.1399-3062.2009.00384.x. Epub 2009 Mar 17.

VKORC1 haplotypes and long-term renal allograft survival.

Pallet N, **Loriot MA**, Anglicheau D, Legendre C, Beaune P, Thervet E.

Transplantation. 2009 Mar 27;87(6):942. doi: 10.1097/TP.0b013e31819b6e12.

[The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer].

Laurent-Puig P, Lièvre A, Ducreux M, **Loriot MA**.

Bull Cancer. 2008 Oct;95(10):935-42. doi: 10.1684/bdc.2008.0728. French.

Glutathione S-transferases related to P. aeruginosa lung infection in cystic fibrosis children: preliminary study.

Feuillet-Fieux MN, Nguyen-Khoa T, **Loriot MA**, Kelly M, de Villartay P, Sermet I, Verrier P, Bonnefont JP, Beaune P, Lenoir G, Lacour B.

Clin Biochem. 2009 Jan;42(1-2):57-63. doi: 10.1016/j.clinbiochem.2008.09.116.

Characterisation of novel defective thiopurine S-methyltransferase allelic variants.

Garat A, Cauffiez C, Renault N, Lo-Guidice JM, Allorge D, Chevalier D, Houdret N, Chavatte P, **Loriot MA**, Gala JL, Broly F.

Biochem Pharmacol. 2008 Aug 1;76(3):404-15. doi: 10.1016/j.bcp.2008.05.009.

Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans.

Bodin L, Perdu J, Diry M, Horellou MH, **Loriot MA**.

J Thromb Haemost. 2008 Aug;6(8):1436-9. doi: 10.1111/j.1538-7836.2008.03049.x.

No clear link between VKORC1 genetic polymorphism and the risk of venous thrombosis or peripheral arterial disease.

Smadja DM, **Loriot MA**, Hindorff LA, Mellottee L, Gaussem P, Emmerich J.

Thromb Haemost. 2008 May;99(5):970-2. doi: 10.1160/TH07-12-0742.

Overanticoagulation with coumarin and cutaneous azole therapy.

Alexandra JF, Pautas E, Gouin-Thibault I, Siguret V, **Loriot MA**.

Ann Intern Med. 2008 Apr 15;148(8):633-5. Erratum in: Ann Intern Med. 2008 May 20;148(10):795. Gouin-Thibault, Isabelle [added]; Siguret, Virginie [added]; Loriot, Marie-Anne [added].

Hepatocellular carcinoma and occupation in men: a case-control study.

Ferrand JF, Cénée S, Laurent-Puig P, **Loriot MA**, Trinchet JC, Degos F, Bronovicky JP, Pelletier G, Stücker I.

J Occup Environ Med. 2008 Feb;50(2):212-20. doi: 10.1097/JOM.0b013e31815d88e2.

Minocycline-induced DRESS: evidence for accumulation of the culprit drug.

Maubec E, Wolkenstein P, **Loriot MA**, Wechsler J, Mulot C, Beaune P, Revuz J, Roujeau JC.

Dermatology. 2008;216(3):200-4. doi: 10.1159/000112926.

[Molecular pharmacogenetics in hospital laboratories in France: current data and future prospects].

Allorge D, Beaune PH, Becquemont L, Bessard G, Bezieau S, Boisdron-Celle M, Boyer JC, Broly F, Dhaneens CM, Fonrose X, Gagnieu MC, Gamelin E, Gozé C, Jacqz-Aigrain E, Loric S, **Loriot MA**, Marquet P, Morel A, Namour B, Paintaud G, Peoc'h K, Picard N, Watier H, Verstuyft C.

Ann Pharm Fr. 2007 Nov;65(6):371-81. Review. French.

UDP-glucuronosyltransferase UGT1A7 genetic polymorphisms in hepatocellular carcinoma: a differential impact according to seropositivity of HBV or HCV markers?

Stücker I, **Loriot MA**, N'koutchou G, Cénée S, Bodin L, Mulot C, Gelu-Simeon M, Pelletier L, Bronowicki JP, Degos F, Beaune P, Laurent-Puig P, Hémon D, Trinchet JC, Pelletier G.

BMC Cancer. 2007 Nov 19;7:214.

Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome P450 enzymes in normal and pathological human brain.

Dutheil F, Beaune P, **Loriot MA**.

Biochimie. 2008 Mar;90(3):426-36.Review.

Acetaminophen reinforces descending inhibitory pain pathways.

Pickering G, Estève V, **Loriot MA**, Eschalier A, Dubray C.

Clin Pharmacol Ther. 2008 Jul;84(1):47-51.

[Pharmacogenetics of oral anticoagulants: individualized drug treatment for more efficacy and safety].

Loriot MA, Beaune P.

Rev Prat. 2007 Jun 30;57(12):1281-6. Review. French.

Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis.

Daniel F, **Loriot MA**, Seksik P, Cosnes J, Gornet JM, Lémann M, Fein F, Vernier-Massouille G, De Vos M, Boureille A, Treton X, Flourié B, Roblin X, Louis E, Zerbib F, Beaune P, Marteau P.

Inflamm Bowel Dis. 2007 Jan;13(1):19-23.

[Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].

Loriot MA, Beaune P.

Rev Med Interne. 2006 Dec;27(12):979-82. Review. French.

Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy.

Lecomte T, Landi B, Beaune P, Laurent-Puig P, **Loriot MA**.

Clin Cancer Res. 2006 May 15;12(10):3050-6.

Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism.

Pickering G, **Loriot MA**, Libert F, Eschalier A, Beaune P, Dubray C.

Clin Pharmacol Ther. 2006 Apr;79(4):371-8.

Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient.

Moreau C, Debray D, **Loriot MA**, Taburet AM, Furlan V.

Transplantation. 2006 Feb 15;81(3):487-8. No abstract available. Erratum in: Transplantation. 2006 Nov 27;82(10):1382.

Association analysis of drug metabolizing enzyme gene polymorphisms in AIDS patients with cutaneous reactions to sulfonamides.

Wolkenstein P, **Loriot MA**, Flahault A, Cadilhac M, Caumes E, Eliasiewicz M, Beaune P, Roujeau JC, Chosidow O; Epitox Group.

J Invest Dermatol. 2005 Nov;125(5):1080-2.

Myeloperoxidase genetic polymorphisms modulate human neutrophil enzyme activity: genetic determinants for atherosclerosis?

Chevrier I, Tregouet DA, Massonnet-Castel S, Beaune P, **Loriot MA**.

Atherosclerosis. 2006 Sep;188(1):150-4.

Childhood leukaemia, polymorphisms of metabolism enzyme genes, and interactions with maternal tobacco, coffee and alcohol consumption during pregnancy.

Clavel J, Bellec S, Rebouissou S, Ménégau F, Feunteun J, Bonaïti-Pellié C, Baruchel A, Kebaili K, Lambilliotte A, Leverger G, Sommelet D, Lescoeur B, Beaune P, Hémon D, **Loriot MA**.

Eur J Cancer Prev. 2005 Dec;14(6):531-40.

Collection of human genomic DNA from buccal cells for genetics studies: comparison between cytobrush, mouthwash, and treated card.

Mulot C, Stücker I, Clavel J, Beaune P, **Loriot MA**.

J Biomed Biotechnol. 2005;2005(3):291-6.

Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR.

Bodin L, Beaune PH, **Loriot MA**.

J Biomed Biotechnol. 2005;2005(3):248-53.

A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance.

Bodin L, Horellou MH, Flaujac C, **Loriot MA**, Samama MM.

J Thromb Haemost. 2005 Jul;3(7):1533-5.

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, **Loriot MA**.

Blood. 2005 Jul 1;106(1):135-40.

[Pharmacogenetics of anticancer drugs].

de Chaisemartin L, **Loriot MA**.

Pathol Biol (Paris). 2005 Mar;53(2):116-24. Review. French.

TEGDMA modulates glutathione transferase P1 activity in gingival fibroblasts.

Lefevre M, Bourd K, **Loriot MA**, Goldberg M, Beaune P, Périanin A, Stanislawski L.

J Dent Res. 2004 Dec;83(12):914-9.

Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.

Lecomte T, Ferraz JM, Zinzindohoué F, **Loriot MA**, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P, Laurent-Puig P.

Clin Cancer Res. 2004 Sep 1;10(17):5880-8.

[Pharmacogenetics or the promise of a personalized medicine: variability in drug metabolism and transport].

Allorge D, **Loriot MA**.

Ann Biol Clin (Paris). 2004 Sep-Oct;62(5):499-511. Review. French.

[Pharmacogenomics: the link between genes and response to drugs].

Loriot MA, Beaune P.

Med Sci (Paris). 2004 Jun-Jul;20(6-7):634-6. French.

Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma.

Zinzindohoué F, Blons H, Hans S, **Loriot MA**, Houllier AM, Brasnu D, Laccourreye O, Tregouet DA, Stucker I, Laurent-Puig P.

Anticancer Res. 2004 May-Jun;24(3b):2021-6.

Pharmacogenetics of acenocoumarol pharmacodynamics.

Morin S, Bodin L, **Loriot MA**, Thijssen HH, Robert A, Strabach S, Verstuyft C, Tregouet DA, Dubert L, Laurent-Puig P, Funck-Brentano C, Jaillon P, Beaune PH, Becquemont L.

Clin Pharmacol Ther. 2004 May;75(5):403-14.

Impact of GSTT1, GSTM1, GSTP1 and NAT2 genotypes on KRAS2 and TP53 gene mutations in colorectal cancer.

Ferraz JM, Zinzindohoué F, Lecomte T, Cugnenc PH, **Loriot MA**, Beaune P, Stücker I, Berger A, Laurent-Puig P.

Int J Cancer. 2004 Jun 10;110(2):183-7.

PMID:15069679[PubMed - indexed for MEDLINE]

Related citations

Select item 1464669271.

Myeloperoxidase: new polymorphisms and relation with lung cancer risk.

Chevrier I, Stücker I, Houllier AM, Cenée S, Beaune P, Laurent-Puig P, **Loriot MA**.

Pharmacogenetics. 2003 Dec;13(12):729-39.

[A new, rapid and robust genotyping method for CYP2C9 and MDR1].

Verstuyft C, Morin S, Yang J, **Loriot MA**, Barbu V, Kerb R, Brinkmann U, Beaune P, Jaillon P, Becquemont L.

Ann Biol Clin (Paris). 2003 May-Jun;61(3):305-9. French.

Genetic and environmental risk factors for oral anticoagulant overdose.

Verstuyft C, Robert A, Morin S, **Loriot MA**, Flahault A, Beaune P, Funck-Brentano C, Jaillon P, Becquemont L.

Eur J Clin Pharmacol. 2003 Mar;58(11):739-45.

Genetic polymorphisms of glutathione S-transferases as modulators of lung cancer susceptibility.

Stücker I, Hirvonen A, de Waziers I, Cabelguenne A, Mitrinen K, Cénée S, Koum-Besson E, Hémon D, Beaune P, **Loriot MA**.

Carcinogenesis. 2002 Sep;23(9):1475-81.

Thiopurine methyltransferase activity: new conditions for reversed-phase high-performance liquid chromatographic assay without extraction and genotypic-phenotypic correlation.

Anglicheau D, Sanquer S, **Loriot MA**, Beaune P, Thervet E.

J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 25;773(2):119-27.

Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.

Verstuyft C, Morin S, Robert A, **Loriot MA**, Beaune P, Jaillon P, Becquemont L.

Pharmacogenetics. 2001 Nov;11(8):735-7.

Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy.

Cabelguenne A, **Loriot MA**, Stucker I, Blons H, Koum-Besson E, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P, De Waziers I.

Int J Cancer. 2001 Sep 1;93(5):725-30.

Is diclofenac a valuable CYP2C9 probe in humans?

Morin S, **Loriot MA**, Poirier JM, Tenneze L, Beaune PH, Funck-Brentano C, Jaillon P, Becquemont L.

Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):793-7.

Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population.

Loriot MA, Rebuissou S, Oscarson M, Cénée S, Miyamoto M, Ariyoshi N, Kamataki T, Hémon D, Beaune P, Stücker I.

Pharmacogenetics. 2001 Feb;11(1):39-44.

Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS.

Wolkenstein P, **Loriot MA**, Aractingi S, Cabelguenne A, Beaune P, Chosidow O.

Pharmacogenetics. 2000 Dec;10(9):821-8.

Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C.

Ariyoshi N, Takahashi Y, Miyamoto M, Umetsu Y, Daigo S, Tateishi T, Kobayashi S, Mizorogi Y, **Loriot MA**, Stücker I, Beaune P, Kinoshita M, Kamataki T.

Pharmacogenetics. 2000 Nov;10(8):687-93.

Permissiveness of human biliary epithelial cells to infection by hepatitis C virus.

Loriot MA, Bronowicki JP, Lagorce D, Lakehal F, Persico T, Barba G, Mergey M, Vons C, Franco D, Belghiti J, Giacca M, Housset C, Bréchet C.

Hepatology. 1999 May;29(5):1587-95.

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

Colin JF, Cazals-Hatem D, **Loriot MA**, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, Benhamou JP, Erlinger S, Valla D, Marcellin P.

Hepatology. 1999 Apr;29(4):1306-10.

Concurrent emergence of hepatitis B e antigen-negative hepatitis B virus variant and autoimmune hepatitis cured by adenine arabinoside monophosphate.

Bécheur H, Valla D, **Loriot MA**, Attar A, Bloch F, Petite JP.

Dig Dis Sci. 1998 Nov;43(11):2479-82. Review.

[Characterization of liver regeneration in the albumin-urokinase transgenic mouse].

Nicolet J, **Loriot MA**, Bonte E, Capron F, Franco D, Bréchet C.

Chirurgie. 1998 Feb;123(1):47-53. French.

Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice.

Bronowicki JP, **Loriot MA**, Thiers V, Grignon Y, Zignego AL, Bréchet C.

Hepatology. 1998 Jul;28(1):211-8.

Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg.

Loriot MA, Marcellin P, Walker F, Boyer N, Degott C, Randrianatoavina I, Benhamou JP, Erlinger S.

J Hepatol. 1997 Aug;27(2):251-8.

Prolonged interferon-alpha therapy of hepatitis B virus-related decompensated cirrhosis.

Marcellin P, Giuily N, **Loriot MA**, Durand F, Samuel D, Bettan L, Degott C, Bernuau J, Benhamou JP, Erlinger S.

J Viral Hepat. 1997;4 Suppl 1:21-6.

Hepatitis B virus precore mutations and HBeAg negative reactivation of chronic hepatitis B after interferon therapy.

Talbodec N, **Loriot MA**, Gigou M, Guigonis V, Boyer N, Bezeaud A, Erlinger S, Benhamou JP, Marcellin P.

Liver. 1995 Apr;15(2):93-8.

Low frequency of precore hepatitis B virus mutants in anti-hepatitis B e-positive reactivation after loss of hepatitis B e antigen in patients with chronic hepatitis B.

Loriot MA, Marcellin P, Talbodec N, Guignonis V, Gigou M, Boyer N, Bezeaud A, Erlinger S, Benhamou JP.

Hepatology. 1995 Mar;21(3):627-31.

Adenine arabinoside 5'-monophosphate in patients with chronic hepatitis B: comparison of the efficacy in patients with high and low viral replication.

Marcellin P, Pouteau M, **Loriot MA**, Boyer N, Degos F, Calès P, Bettan L, Bacq Y, Coppère H, Grange JD, et al.

Gut. 1995 Mar;36(3):422-6.

Fatal reactivation of hepatitis B virus mutant following cytotoxic treatment.

Duclos-Vallee JC, Laurent-Puig P, **Loriot MA**, Buffet C, Malka D, Pelletier G, Marcellin P, Erlinger S, Etienne JP.

J Hepatol. 1994 Dec;21(6):1152. No abstract available.

Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease.

Marcellin P, Samuel D, Areias J, **Loriot MA**, Arulnaden JL, Gigou M, David MF, Bismuth A, Reynes M, Bréchet C, et al.

Hepatology. 1994 Jan;19(1):6-12.

Detection of serum HBV-DNA by polymerase chain reaction (PCR) in patients before reactivation of chronic hepatitis B.

Gayno S, Marcellin P, **Loriot MA**, Martinot-Peignoux M, Levy P, Erlinger S, Benhamou JP.

J Hepatol. 1992 Mar;14(2-3):357-60.

Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B.

Loriot MA, Marcellin P, Bismuth E, Martinot-Peignoux M, Boyer N, Degott C, Erlinger S, Benhamou JP.

Hepatology. 1992 Jan;15(1):32-6.

Anti-pre-S responses and viral clearance in chronic hepatitis B virus infection.

Budkowska A, Dubreuil P, Poynard T, Marcellin P, **Loriot MA**, Maillard P, Pillot J.

Hepatology. 1992 Jan;15(1):26-31.

Redevelopment of hepatitis B surface antigen after renal transplantation.

Marcellin P, Giostra E, Martinot-Peignoux M, **Loriot MA**, Jaegle ML, Wolf P, Degott C, Degos F, Benhamou JP.

Gastroenterology. 1991 May;100(5 Pt 1):1432-4.

Is the response to recombinant alpha interferon related to the presence of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis?

Marcellin P, Giostra E, Boyer N, **Loriot MA**, Martinot-Peignoux M, Benhamou JP.

J Hepatol. 1990 Jul;11(1):77-9.

Recombinant human gamma-interferon in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects.

Marcellin P, **Loriot MA**, Boyer N, Martinot-Peignoux M, Degott C, Degos F, Brandely M, Lenfant B, Benhamou JP.

Hepatology. 1990 Jul;12(1):155-8.

Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy.

Marcellin P, Martinot-Peignoux M, **Loriot MA**, Giostra E, Boyer N, Thiers V, Benhamou JP.

Ann Intern Med. 1990 Feb 1;112(3):227-8.

Absence of effect of zidovudine on replication of hepatitis B virus in patients with chronic HIV and HBV infection.

Marcellin P, Pialoux G, Girard PM, Boyer N, Martinot-Peignoux M, **Loriot MA**, Dazza MC, Benhamou JP.

N Engl J Med. 1989 Dec 21;321(25):1758.